Literature DB >> 8119638

Current conservative treatment of acute pancreatitis: evidence from animal and human studies.

C Niederau1, H U Schulz.   

Abstract

Primary treatment of patients suffering from acute pancreatitis is conservative, irrespective of its etiology and initial severity. There is no effective specific therapy for treating the underlying disease process. As a result, the current therapeutic approach involves the provision of supportive care, the elimination of causal (biliary tract) disease, and the treatment of complications. Since complications may develop at any time, patients with moderate or severe disease should be admitted to an intensive care unit for interdisciplinary assessment and constant observation of their clinical status and computed tomography findings. Basic therapy should include total fasting, replacement of deficits in volume, electrolyte and albumin, as well as adequate analgesia. Depending on the patient's specific clinical condition, nasogastric suction, respiratory support, antibiotics, insulin and heparin may become necessary. The use of enzyme inhibitors and drugs capable of inhibiting pancreatic exocrine secretion has not proved effective in clinical trials. The value of prostaglandins, non-steroidal anti-inflammatory drugs and cholecystokinin receptor antagonists remains to be established. Early endoscopic retrograde cholangiopancreatography should be performed in patients with suspected underlying biliary disease. Papillotomy should be carried out only when calculi are present in the common bile duct. Local complications, such as pseudocysts and abscesses can often be treated by ultrasound- or CT-guided aspiration and drainage. However, when bacterial infection of pancreatic necrosis becomes evident, surgical intervention should be considered. Future evaluation of new therapeutic approaches by controlled studies needs to include a sufficient number of patients with severe acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8119638

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

1.  Complicated Acute Pancreatitis.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

2.  Specific therapy for local and systemic complications of acute pancreatitis with monoclonal antibodies against ICAM-1.

Authors:  J Werner; K Z'graggen; C Fernández-del Castillo; K B Lewandrowski; C C Compton; A L Warshaw
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

3.  Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis.

Authors:  C D Johnson; A N Kingsnorth; C W Imrie; M J McMahon; J P Neoptolemos; C McKay; S K Toh; P Skaife; P C Leeder; P Wilson; M Larvin; L D Curtis
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

Review 4.  Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach?

Authors:  Young Koog Cheon
Journal:  Korean J Intern Med       Date:  2013-02-27       Impact factor: 2.884

Review 5.  Acute pancreatitis: the substantial human and financial costs.

Authors:  J P Neoptolemos; M Raraty; M Finch; R Sutton
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

6.  Effects of C1-esterase inhibitor in three models of acute pancreatitis.

Authors:  C Niederau; R Brinsa; M Niederau; R Lüthen; G Strohmeyer; L D Ferrell
Journal:  Int J Pancreatol       Date:  1995-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.